Kabra Drugs goes from zero revenue to ₹92.74 cr in one year
The nano-cap swung to a ₹4.96 cr profit after a ₹1.08 cr loss last year. A new manufacturing strategy delivered ₹35 cr in the final quarter alone.
— 2 earlier stories on Kabra Drugs Ltd. →What's new
- Kabra Drugs reported FY26 revenue of ₹92.74 cr, having recorded no revenue the prior year.
- Net profit came in at ₹4.96 cr, reversing a FY25 net loss of ₹1.08 cr.
- Q4 contributed over ₹35 cr, signaling the ramp is accelerating.
Why this matters
For a company with a ₹59 cr market cap, a ₹92.74 cr topline from a standing start is not incremental growth—it's a business reset. The move into multi-sector manufacturing has produced tangible results, and auditors signed off without qualification. The numbers are real.
What we're watching
- Whether the ₹92.74 cr run-rate holds or if FY25 was a one-off contract cycle.
- Margin profile once the new manufacturing operations mature.
- Whether the concessional tax regime provides a meaningful profit tailwind in FY27.
The full read
Kabra Drugs went from zero revenue in FY25 to ₹92.74 crore in FY26. That is not a recovery. It is the start of a different company. The ₹4.96 crore net profit reverses a ₹1.08 crore loss, and auditors signed off without qualification. For a firm with a ₹59 crore market cap, the scale of the shift is hard to overstate. Over ₹35 crore of that revenue arrived in the final quarter, so the business is still ramping. The company says it has moved into new manufacturing sectors and shifted to a concessional tax regime. Both moves are now in the numbers. The open question is whether the contracts that drove the ₹92.74 crore topline are recurring or project-based.
Questions answered
- How did Kabra Drugs generate ₹92.74 cr in revenue from zero?
- The company diversified into new manufacturing sectors during FY26. The results note this strategic shift as the source of the new revenue stream, with Q4 alone contributing over ₹35 cr.
- Is the profit sustainable, or is it a one-time event?
- The results are audited with an unmodified opinion, and the company has transitioned to a concessional tax regime. However, the move from zero revenue is so abrupt that the durability of the ₹4.96 cr profit will depend entirely on whether the new manufacturing contracts continue.
- How large is Kabra Drugs in market-cap terms?
- The rationale cites a market capitalization of ₹59 cr, making this a nano-cap company where a ₹92.74 cr revenue base is a dramatic change in scale.
Story so far
All notes on KABRADG →- 29 May 2026 · 10:21 PM IST Kabra Drugs goes from zero revenue to ₹92.74 cr in one year
- today Kabra Drugs lands ₹200 cr LOI from Chhattisgarh for pharma plant
- 15d ago Kabra Drugs' revenue jumped from zero to ₹92.74 cr in a single year